Tetramethylcurcumin

Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects[1][2].

Product Specifications

CAS Number

[52328-97-9]

Product Name Alternative

FLLL31

UNSPSC

12352005

Hazard Statement

H413

Target

Apoptosis; STAT

Related Pathways

Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COC1=C(C=CC(/C=C/C(C(C)(C)C(/C=C/C2=CC(OC)=C(OC)C=C2)=O)=O)=C1)OC

Molecular Formula

C25H28O6

Molecular Weight

424.49

Precautions

H413

References & Citations

[1]Lin L, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010 Mar 15;70 (6) :2445-54.|[2]Yuan S, et al. FLLL31, a derivative of curcumin, attenuates airway inflammation in a multi-allergen challenged mouse model. Int Immunopharmacol. 2014 Jul;21 (1) :128-36.